Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Treating Tissue Factor-Positive Cancers with Antibody-Drug Conjugates That Do Not Affect Blood Clotting.

Theunissen JW, Cai AG, Bhatti MM, Cooper AB, Avery AD, Dorfman R, Guelman S, Levashova Z, Migone TS.

Mol Cancer Ther. 2018 Nov;17(11):2412-2426. doi: 10.1158/1535-7163.MCT-18-0471. Epub 2018 Aug 20.

2.

Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan S, Wong T, Melnick J, Theunissen JW, Flory MR, Houser D, Venstrom K, Levashova Z, Sauer P, Migone TS, van der Horst EH, Halcomb RL, Jackson DY.

Mol Pharm. 2015 Nov 2;12(11):3986-98. doi: 10.1021/acs.molpharmaceut.5b00432. Epub 2015 Oct 2.

PMID:
26393951
3.

A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.

Kim SY, Theunissen JW, Balibalos J, Liao-Chan S, Babcock MC, Wong T, Cairns B, Gonzalez D, van der Horst EH, Perez M, Levashova Z, Chinn L, D'Alessio JA, Flory M, Bermudez A, Jackson DY, Ha E, Monteon J, Bruhns MF, Chen G, Migone TS.

Blood Cancer J. 2015 May 29;5:e316. doi: 10.1038/bcj.2015.39.

4.

Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.

Migone TS, Bolmer S, Zhong J, Corey A, Vasconcelos D, Buccellato M, Meister G.

Antimicrob Agents Chemother. 2015 Feb;59(2):1145-51. doi: 10.1128/AAC.04606-14. Epub 2014 Dec 8.

5.

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation.

Goenka R, Matthews AH, Zhang B, O'Neill PJ, Scholz JL, Migone TS, Leonard WJ, Stohl W, Hershberg U, Cancro MP.

J Exp Med. 2014 Jan 13;211(1):45-56. doi: 10.1084/jem.20130505. Epub 2013 Dec 23.

6.

The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of γ-herpesvirus infected B cells in the marmoset EAE model.

Anwar Jagessar S, Fagrouch Z, Heijmans N, Bauer J, Laman JD, Oh L, Migone T, Verschoor EJ, 't Hart BA.

J Neuroimmune Pharmacol. 2013 Jun;8(3):727-38. doi: 10.1007/s11481-013-9448-6. Epub 2013 Mar 19.

PMID:
23508625
7.

Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.

Corey A, Migone TS, Bolmer S, Fiscella M, Ward C, Chen C, Meister G.

Toxins (Basel). 2013 Jan 14;5(1):120-38. doi: 10.3390/toxins5010120.

8.

Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.

Jacob CO, Yu N, Guo S, Jacob N, Quinn WJ 3rd, Sindhava V, Cancro MP, Goilav B, Putterman C, Migone TS, Stohl W.

Arthritis Rheum. 2013 Apr;65(4):1043-54. doi: 10.1002/art.37846.

9.

Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.

Luster TA, Mukherjee I, Carrell JA, Cho YH, Gill J, Kelly L, Garcia A, Ward C, Oh L, Ullrich SJ, Migone TS, Humphreys R.

PLoS One. 2012;7(10):e47361. doi: 10.1371/journal.pone.0047361. Epub 2012 Oct 9.

10.

BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies.

Thibault-Espitia A, Foucher Y, Danger R, Migone T, Pallier A, Castagnet S, G-Gueguen C, Devys A, C-Gautier A, Giral M, Soulillou JP, Brouard S.

Am J Transplant. 2012 Oct;12(10):2754-62. doi: 10.1111/j.1600-6143.2012.04194.x. Epub 2012 Aug 6.

11.

Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.

Jagessar SA, Heijmans N, Oh L, Bauer J, Blezer EL, Laman JD, Migone TS, Devalaraja MN, 't Hart BA.

J Neuroimmune Pharmacol. 2012 Sep;7(3):557-70. doi: 10.1007/s11481-012-9384-x. Epub 2012 Jun 30. Erratum in: J Neuroimmune Pharmacol. 2013 Mar;8(1):370. Oh, Luke [added].

12.

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.

Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS; BLISS-76 Study Group.

J Rheumatol. 2012 Aug;39(8):1632-40. Epub 2012 Jun 15.

13.

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group.

Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400.

14.

Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF.

Parsons RF, Yu M, Vivek K, Zekavat G, Rostami SY, Ziaie AS, Luo Y, Koeberlein B, Redfield RR, Ward CD, Migone TS, Cancro MP, Naji A, Noorchashm H.

Transplantation. 2012 Apr 15;93(7):676-85. doi: 10.1097/TP.0b013e318246621d.

PMID:
22262127
15.

Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines.

Barochia AV, Cui X, Sun J, Li Y, Solomon SB, Migone TS, Subramanian GM, Bolmer SD, Eichacker PQ.

J Infect Dis. 2012 Mar 1;205(5):818-29. doi: 10.1093/infdis/jir834. Epub 2012 Jan 5.

16.

Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice.

Jacob CO, Guo S, Jacob N, Pawar RD, Putterman C, Quinn WJ 3rd, Cancro MP, Migone TS, Stohl W.

Arthritis Rheum. 2012 May;64(5):1610-9. doi: 10.1002/art.33458.

17.

CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques.

Taaffe JE, Bosinger SE, Del Prete GQ, Else JG, Ratcliffe S, Ward CD, Migone T, Paiardini M, Silvestri G.

J Med Primatol. 2012 Feb;41(1):24-42. doi: 10.1111/j.1600-0684.2011.00521.x. Epub 2011 Nov 14.

18.

Strategies for B-lymphocyte repertoire remodeling in transplantation tolerance.

Vivek K, Mustafa MM, Rodriguez E, Redfield RR 3rd, Parsons RF, Rostami S, Migone TS, Cancro MP, Naji A, Noorchashm H.

Immunol Res. 2011 Oct;51(1):1-4. doi: 10.1007/s12026-011-8246-6. Review.

PMID:
21948256
19.

Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments.

Nikbakht N, Migone TS, Ward CP, Manser T.

J Immunol. 2011 Jul 1;187(1):37-46. doi: 10.4049/jimmunol.1003924. Epub 2011 Jun 1.

20.

Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines.

Sweeney DA, Cui X, Solomon SB, Vitberg DA, Migone TS, Scher D, Danner RL, Natanson C, Subramanian GM, Eichacker PQ.

J Infect Dis. 2010 Dec 15;202(12):1885-96. doi: 10.1086/657408. Epub 2010 Nov 10.

21.

The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation.

Meylan F, Song YJ, Fuss I, Villarreal S, Kahle E, Malm IJ, Acharya K, Ramos HL, Lo L, Mentink-Kane MM, Wynn TA, Migone TS, Strober W, Siegel RM.

Mucosal Immunol. 2011 Mar;4(2):172-85. doi: 10.1038/mi.2010.67. Epub 2010 Oct 27.

22.

B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.

Parsons RF, Vivek K, Redfield RR 3rd, Migone TS, Cancro MP, Naji A, Noorchashm H.

Transplant Rev (Orlando). 2010 Oct;24(4):207-21. doi: 10.1016/j.trre.2010.05.004. Epub 2010 Jul 23. Review.

23.

Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice.

Scapini P, Hu Y, Chu CL, Migone TS, Defranco AL, Cassatella MA, Lowell CA.

J Exp Med. 2010 Aug 2;207(8):1757-73. doi: 10.1084/jem.20100086. Epub 2010 Jul 12.

24.

G alpha q-containing G proteins regulate B cell selection and survival and are required to prevent B cell-dependent autoimmunity.

Misra RS, Shi G, Moreno-Garcia ME, Thankappan A, Tighe M, Mousseau B, Kusser K, Becker-Herman S, Hudkins KL, Dunn R, Kehry MR, Migone TS, Marshak-Rothstein A, Simon M, Randall TD, Alpers CE, Liggitt D, Rawlings DJ, Lund FE.

J Exp Med. 2010 Aug 2;207(8):1775-89. doi: 10.1084/jem.20092735. Epub 2010 Jul 12.

25.

B-cell homeostasis requires complementary CD22 and BLyS/BR3 survival signals.

Smith SH, Haas KM, Poe JC, Yanaba K, Ward CD, Migone TS, Tedder TF.

Int Immunol. 2010 Aug;22(8):681-91. doi: 10.1093/intimm/dxq055. Epub 2010 May 31.

26.

B-cell tolerance in transplantation: is repertoire remodeling the answer?

Parsons RF, Vivek K, Redfield RR, Migone TS, Cancro MP, Naji A, Noorchashm H.

Expert Rev Clin Immunol. 2009 Nov;5(6):703.

27.

B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.

Hong SD, Reiff A, Yang HT, Migone TS, Ward CD, Marzan K, Shaham B, Phei WC, Garza J, Bernstein B, Stohl W.

Arthritis Rheum. 2009 Nov;60(11):3400-9. doi: 10.1002/art.24902.

28.

Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator.

Auyeung-Kim DJ, Devalaraja MN, Migone TS, Cai W, Chellman GJ.

Reprod Toxicol. 2009 Dec;28(4):443-55. doi: 10.1016/j.reprotox.2009.07.002. Epub 2009 Jul 23.

PMID:
19631735
29.

Raxibacumab for the treatment of inhalational anthrax.

Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD.

N Engl J Med. 2009 Jul 9;361(2):135-44. doi: 10.1056/NEJMoa0810603.

30.

Changes in B-lymphocyte stimulator protein levels during treatment with albinterferon alfa-2b in patients with chronic hepatitis C who have failed previous interferon therapy.

Rustgi V, Nelson DR, Balan V, Abelson RD, Fiscella M, Migone TS, Pulkstenis E, Subramanian GM.

Hepatol Res. 2009 May 1;39(5):455-62. doi: 10.1111/j.1872-034X.2008.00475.x. Epub 2008 Dec 30.

PMID:
20849568
31.

In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice.

Zekavat G, Rostami SY, Badkerhanian A, Parsons RF, Koeberlein B, Yu M, Ward CD, Migone TS, Yu L, Eisenbarth GS, Cancro MP, Naji A, Noorchashm H.

J Immunol. 2008 Dec 1;181(11):8133-44.

32.

BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact.

Scholz JL, Crowley JE, Tomayko MM, Steinel N, O'Neill PJ, Quinn WJ 3rd, Goenka R, Miller JP, Cho YH, Long V, Ward C, Migone TS, Shlomchik MJ, Cancro MP.

Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15517-22. doi: 10.1073/pnas.0807841105. Epub 2008 Oct 1.

33.
34.

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.

Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.

Ann Rheum Dis. 2008 Jul;67(7):1011-6. Epub 2007 Oct 25.

PMID:
17962238
35.

Elevated serum BLyS levels in patients with non-Hodgkin lymphoma.

Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A.

Leuk Lymphoma. 2007 Sep;48(9):1869-71. No abstract available.

PMID:
17786728
36.

Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma.

Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A.

Haematologica. 2007 Feb;92(2):269-70.

37.

B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection.

Fabris M, Quartuccio L, Sacco S, De Marchi G, Pozzato G, Mazzaro C, Ferraccioli G, Migone TS, De Vita S.

Rheumatology (Oxford). 2007 Jan;46(1):37-43. Epub 2006 May 30.

PMID:
16735452
40.

Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.

Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P, Chen G, Stolow D, Halpern WG, Migone TS, Wang Q, Grzegorzewski KJ, Gallant G.

Cancer Immunol Immunother. 2005 Jun;54(6):535-47. Epub 2004 Dec 8.

PMID:
15592670
41.

Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.

Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W.

Arthritis Rheum. 2003 Apr;48(4):982-92.

42.

TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model.

Fiscella M, Perry JW, Teng B, Bloom M, Zhang C, Leung K, Pukac L, Florence K, Concepcion A, Liu B, Meng Y, Chen C, Elgin EC, Kanakaraj P, Kaufmann TE, Porter J, Cibotti R, Mei Y, Zhou J, Chen G, Roschke V, Komatsoulis G, Mansfield B, Ruben S, Sanyal I, Migone TS.

Nat Biotechnol. 2003 Mar;21(3):302-7. Epub 2003 Feb 24.

PMID:
12598909
43.

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases.

Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS.

J Immunol. 2002 Oct 15;169(8):4314-21.

44.

TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P.

Immunity. 2002 Mar;16(3):479-92.

45.
46.

BLyS BINDS TO B CELLS WITH HIGH AFFINITY AND INDUCES ACTIVATION OF THE TRANSCRIPTION FACTORS NF-kappaB AND ELF-1.

Kanakaraj P, Migone TS, Nardelli B, Ullrich S, Li Y, Olsen HS, Salcedo TW, Kaufman T, Cochrane E, Gan Y, Hilbert DM, Giri J.

Cytokine. 2001 Jan 7;13(1):25-31.

PMID:
11145839
47.

Synthesis and release of B-lymphocyte stimulator from myeloid cells.

Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, Sosnovtseva S, Carrell JA, Feng P, Giri JG, Hilbert DM.

Blood. 2001 Jan 1;97(1):198-204.

PMID:
11133761
48.

Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS.

Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, Dimke D, LaFleur D, Migone TS, Nardelli B, Wei P, Ruben SM, Ullrich SJ, Olsen HS, Kanakaraj P, Moore PA, Baker KP.

J Biol Chem. 2000 Nov 10;275(45):35478-85.

49.

CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling.

Aman MJ, Migone TS, Sasaki A, Ascherman DP, Zhu Mh, Soldaini E, Imada K, Miyajima A, Yoshimura A, Leonard WJ.

J Biol Chem. 1999 Oct 15;274(42):30266-72.

50.

SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation.

Cohney SJ, Sanden D, Cacalano NA, Yoshimura A, Mui A, Migone TS, Johnston JA.

Mol Cell Biol. 1999 Jul;19(7):4980-8.

Supplemental Content

Loading ...
Support Center